Amneal Pharmaceuticals (AMRX) Stock Analysis & Winston Score

Amneal Pharmaceuticals makes and sells generic and specialty medicines in the United States and internationally. Its generic drugs are cheaper copies of brand-name medications, sold mainly to pharmacies, hospitals, and drug distributors. The company also has a specialty segment focused on branded drugs, including treatments for movement disorders like Parkinson's disease under its Impax legacy portfolio. Amneal earns money primarily by selling finished drug products — both generic pills and branded specialty medicines — to wholesale distributors and retail pharmacy chains. It operates mostly in the US, with some international presence, and generates roughly $2–3 billion in annual revenue. Its competitive position in generics relies on manufacturing scale and a broad product pipeline, but generic drug pricing is intensely competitive and subject to ongoing price erosion. The key growth driver is expanding its specialty portfolio, particularly injectable and complex generics, though heavy debt from past acquisitions remains a meaningful financial risk.